Prn-4011

Separate from its Nrf2 activity, preliminary data indicates that PRN-4011 may directly stabilize the mitochondrial membrane. In ischemic conditions, the mPTP opens, collapsing the mitochondrial membrane potential and releasing cytochrome c. PRN-4011 appears to increase the threshold for mPTP opening, preserving ATP synthesis.

| Feature | Edaravone (Approved) | NXY-059 (Failed) | | | :--- | :--- | :--- | :--- | | Primary Target | Free radical scavenging | Nitrone-based trapping | Nrf2 activation + mPTP | | CNS Penetration | Moderate | Low | High (1.4:1 ratio) | | Therapeutic Window | < 2 hours | < 4 hours | Targeting > 6 hours | | Route of Admin | IV infusion | IV infusion | Oral bioavailability (60%) | prn-4011

While full pharmacological data for PRN-4011 remains under wraps, identifiers of this format typically point to one of the following: Separate from its Nrf2 activity, preliminary data indicates